Pathologic complete response to conversion therapy in hepatocellular carcinoma using patient-derived organoids: A...

Area of Science:

• Oncology
• Translational Medicine

Background:

• Effective drug treatment is crucial for conversion therapy in primary liver cancer.
• Patient-derived tumor organoids (PDOs) show promise in identifying targeted therapies but their clinical impact in liver cancer is unproven.

Observation:

• A case study details a hepatocellular carcinoma (HCC) patient undergoing conversion therapy guided by PDO drug sensitivity testing.
• The patient achieved significant tumor reduction and was able to undergo successful surgical resection despite limited liver volume post-treatment.

Findings:

• The patient experienced a pathologic complete response (pCR) following the personalized treatment strategy.
• PDOs facilitated the selection of drugs effective for the individual patient's tumor.

Implications:

• PDOs can enhance the efficacy of conversion therapy for HCC by enabling personalized treatment strategies.
• This approach holds potential for improving outcomes in liver cancer patients.